A Claudio Cuello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8206983/publications.pdf Version: 2024-02-01

		29994	34900
203	11,172	54	98
papers	citations	h-index	g-index
213	213	213	9933
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain, 2018, 141, 1917-1933.	3.7	1,008
2	The distribution of substance P immunoreactive fibers in the rat central nervous system. Journal of Comparative Neurology, 1978, 178, 129-156.	0.9	715
3	Translational control of hippocampal synaptic plasticity and memory by the elF2 \hat{l} ± kinase GCN2. Nature, 2005, 436, 1166-1170.	13.7	344
4	The central and peripheral ends of the substance P-containing sensory neurones in the rat trigeminal system. Brain Research, 1978, 152, 499-509.	1.1	340
5	Evidence for the existence of substance P-containing fibres in striato-nigral and pallido-nigral pathways in rat brain. Brain Research, 1977, 119, 447-453.	1.1	333
6	Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6735-6740.	3.3	312
7	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology, 2020, 11, 456.	2.2	201
8	Reorganization of Cholinergic Terminals in the Cerebral Cortex and Hippocampus in Transgenic Mice Carrying Mutated Presenilin-1 and Amyloid Precursor Protein Transgenes. Journal of Neuroscience, 1999, 19, 2706-2716.	1.7	193
9	Substance P containing and cholinergic projections from the habenula. Brain Research, 1978, 149, 413-429.	1.1	189
10	The anatomy of the CNS cholinergic neurons. Trends in Neurosciences, 1984, 7, 74-78.	4.2	187
11	A Novel Transgenic Rat Model with a Full Alzheimer's-Like Amyloid Pathology Displays Pre-Plaque Intracellular Amyloid-β-Associated Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 20, 113-126.	1.2	187
12	CENTRAL DISTRIBUTION OF OPIOID PEPTIDES. British Medical Bulletin, 1983, 39, 11-16.	2.7	169
13	Modeling Alzheimer's disease in transgenic rats. Molecular Neurodegeneration, 2013, 8, 37.	4.4	144
14	Depletion of substance P-containing axons in substantia gelatinosa of patients with diminished pain sensitivity. Nature, 1982, 295, 61-63.	13.7	132
15	Choline acetyltransferase-immunoreactive profiles are presynaptic to primary sensory fibers in the rat superficial dorsal horn. Journal of Comparative Neurology, 1990, 295, 370-384.	0.9	131
16	Increased Matrix Metalloproteinase 9 Activity in Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1309-1318.	0.9	130
17	The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiology of Aging, 2006, 27, 1644-1657.	1.5	129
18	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. Trends in Pharmacological Sciences, 2014, 35, 338-348.	4.0	127

#	Article	IF	CITATIONS
19	Intracellular AÎ ² -oligomers and early inflammation in a model of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1329-1342.	1.5	126
20	Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2249-2262.	1.5	123
21	Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 857-869.	0.9	122
22	Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?. Trends in Pharmacological Sciences, 2017, 38, 956-966.	4.0	119
23	Paradoxical Upregulation of Glutamatergic Presynaptic Boutons during Mild Cognitive Impairment. Journal of Neuroscience, 2007, 27, 10810-10817.	1.7	117
24	Cholinergic Involvement in Alzheimer's Disease. A Link with NGF Maturation and Degradation. Journal of Molecular Neuroscience, 2010, 40, 230-235.	1.1	111
25	Immunoreactivity for substance P in the gasserian ganglion, ophthalmic nerve and anterior segment of the rabbit eye. The Histochemical Journal, 1981, 13, 435-443.	0.6	106
26	Immunohistochemical demonstration of some putative neurotransmitters in the lamprey spinal cord and spinal ganglia: 5-hydroxytryptamine-, tachykinin-, and neuropeptide-Y-immunoreactive neurons and fibers. Journal of Comparative Neurology, 1985, 234, 501-522.	0.9	105
27	ADAM-10 over-expression increases cortical synaptogenesis. Neurobiology of Aging, 2008, 29, 554-565.	1.5	98
28	Altered synaptic function in Alzheimer's disease. European Journal of Pharmacology, 2006, 545, 11-21.	1.7	95
29	Immunocytoehemical localization of substance P in the spinal trigeminal nucleus of the rat: A light and electron microscopic study. Journal of Comparative Neurology, 1982, 211, 31-49.	0.9	92
30	Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. Journal of Neuroinflammation, 2012, 9, 62.	3.1	89
31	Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?. Current Alzheimer Research, 2011, 8, 164-174.	0.7	88
32	Purkinje cells of adult rat cerebellum express nerve growth factor receptor immunoreactivity: light microscopic observations. Brain Research, 1988, 455, 182-186.	1.1	87
33	Long-Lasting Rescue of Age-Associated Deficits in Cognition and the CNS Cholinergic Phenotype by a Partial Agonist Peptidomimetic Ligand of TrkA. Journal of Neuroscience, 2004, 24, 8009-8018.	1.7	84
34	Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathologica Communications, 2014, 2, 61.	2.4	84
35	Impact of the NGF Maturation and Degradation Pathway on the Cortical Cholinergic System Phenotype. Journal of Neuroscience, 2012, 32, 2002-2012.	1.7	83
36	5-Hydroxytryptamine, substance P, and thyrotropin-releasing hormone in the adult cat spinal cord segment L7: Immunohistochemical and chemical studies. Synapse, 1990, 6, 237-270.	0.6	79

#	Article	IF	CITATIONS
37	Precision pharmacology for Alzheimer's disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
38	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. Alzheimer's and Dementia, 2018, 14, 1204-1215.	0.4	79
39	Substance P immunoreactive neurons following neonatal administration of capsaicin. Naunyn-Schmiedeberg's Archives of Pharmacology, 1981, 315, 185-194.	1.4	78
40	A TrkA-selective, Fast Internalizing Nerve Growth Factor-Antibody Complex Induces Trophic but Not Neuritogenic Signals. Journal of Biological Chemistry, 1998, 273, 34933-34940.	1.6	78
41	NGF-Cholinergic Dependency in Brain Aging, MCI and Alzheimers Disease. Current Alzheimer Research, 2007, 4, 351-358.	0.7	78
42	Engagement of the PFC in consolidation and recall of recent spatial memory. Learning and Memory, 2010, 17, 297-305.	0.5	78
43	Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain, 2014, 137, 860-872.	3.7	75
44	An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimer's and Dementia, 2016, 12, 1132-1148.	0.4	75
45	elF2α controls memory consolidation via excitatory and somatostatin neurons. Nature, 2020, 586, 412-416.	13.7	74
46	The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology. Frontiers in Neuroscience, 2019, 13, 62.	1.4	73
47	Intracellular A-Beta Amyloid, A Sign for Worse Things to Come?. Molecular Neurobiology, 2002, 26, 299-316.	1.9	72
48	Loss of Presynaptic and Postsynaptic Structures Is Accompanied by Compensatory Increase in Action Potential-Dependent Synaptic Input to Layer V Neocortical Pyramidal Neurons in Aged Rats. Journal of Neuroscience, 2000, 20, 8596-8606.	1.7	70
49	Rat transgenic models with a phenotype of intracellular AÎ ² accumulation in hippocampus and cortex. Journal of Alzheimer's Disease, 2004, 6, 209-219.	1.2	70
50	Intracellular and Extracellular Aβ, a Tale of Two Neuropathologies. Brain Pathology, 2005, 15, 66-71.	2.1	66
51	The Failure in NGF Maturation and its Increased Degradation as the Probable Cause for the Vulnerability of Cholinergic Neurons in Alzheimer's Disease. Neurochemical Research, 2007, 32, 1041-1045.	1.6	66
52	Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. Neurobiology of Disease, 2017, 108, 307-323.	2.1	66
53	Evidence of intraneuronal Al² accumulation preceding tau pathology in the entorhinal cortex. Acta Neuropathologica, 2018, 136, 901-917.	3.9	65
54	Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6844-6854.	3.3	62

#	Article	IF	CITATIONS
55	Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. Frontiers in Behavioral Neuroscience, 2014, 8, 321.	1.0	61
56	Connecting the "Dots― From Free Radical Lipid Autoxidation to Cell Pathology and Disease. Chemical Reviews, 2020, 120, 12757-12787.	23.0	61
57	Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain, 2020, 143, 3653-3671.	3.7	59
58	NLRP3-dependent synaptic plasticity deficit in an Alzheimer's disease amyloidosis model in vivo. Neurobiology of Disease, 2018, 114, 24-30.	2.1	58
59	Aβ-induced vulnerability propagates via the brain's default mode network. Nature Communications, 2019, 10, 2353.	5.8	58
60	The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. Current Alzheimer Research, 2015, 13, 53-67.	0.7	57
61	A Progressive Deposition of Paired Helical Filaments (PHF) in the Brain Characterizes the Evolution of Dementia in Alzheimer's Disease Journal of Neuropathology and Experimental Neurology, 1991, 50, 474-490.	0.9	56
62	Aß Immunoreactive Material Is Present in Several Intracellular Compartments in Transfected, Neuronally Differentiated, P19 Cells Expressing the Human Amyloid ÄŸ-Protein Precursor. Journal of Alzheimer's Disease, 2000, 2, 207-222.	1.2	56
63	Peripheral nerve injury leads to the establishment of a novel pattern of sympathetic fibre innervation in the rat skin. , 2000, 422, 287-296.		56
64	Glycosphingolipids that Can Regulate Nerve Growth and Repair. Advances in Pharmacology, 1990, 21, 1-50.	1.2	55
65	Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2014, 40, 667-678.	1.2	55
66	Tau Function and Dysfunction in Neurons. Molecular Neurobiology, 2002, 25, 213-232.	1.9	54
67	Reimagining cholinergic therapy for Alzheimer's disease. Brain, 2022, 145, 2250-2275.	3.7	50
68	Rescue of Early bace-1 and Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves Cognition in an Alzheimer's Model. Scientific Reports, 2016, 6, 34051.	1.6	49
69	Aging Causes a Preferential Loss of Cholinergic Innervation of Characterized Neocortical Pyramidal Neurons. Cerebral Cortex, 2002, 12, 329-337.	1.6	48
70	Ectopic Substance P and Calcitonin Gene-related Peptide Immunoreactive Fibres in the Spinal Cord of Transgenic Mice Over-expressing Nerve Growth Factor. European Journal of Neuroscience, 1995, 7, 2021-2035.	1.2	47
71	Early-Stage Inflammation and Experimental Therapy in Transgenic Models of the Alzheimer-Like Amyloid Pathology. Neurodegenerative Diseases, 2010, 7, 96-98.	0.8	47
72	Neurotransmitter-specific projection neurons revealed by combining PAP immunohistochemistry with retrograde transport of HRP. Brain Research, 1981, 220, 231-240.	1.1	46

#	Article	IF	CITATIONS
73	Mitochondrial abnormalities in neuroectodermal cells stably expressing human amyloid precursor protein (hAPP751). NeuroReport, 1999, 10, 41-46.	0.6	45
74	Skin blood vessels are simultaneously innervated by sensory, sympathetic, and parasympathetic fibers. Journal of Comparative Neurology, 2002, 448, 323-336.	0.9	45
75	Therapeutic benefits of the methyl donor S-adenosylmethionine on nerve injury–induced mechanical hypersensitivity and cognitive impairment in mice. Pain, 2017, 158, 802-810.	2.0	45
76	Association of cerebrospinal fluid αâ€synuclein with total and phosphoâ€tau ₁₈₁ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. Alzheimer's and Dementia, 2018, 14, 1623-1631.	0.4	45
77	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. Journal of Neuroscience, 2017, 37, 12263-12271.	1.7	44
78	Loss of substance P and Enkephalin immunoreactivity in the human substantia nigra after striato-pallidal infarction. Brain Research, 1984, 292, 339-347.	1.1	43
79	Chapter 33 Effects of trophic factors on the CNS cholinergic phenotype. Progress in Brain Research, 1996, 109, 347-358.	0.9	43
80	Transgenic Mice as a Model of Pre-Clinical Alzheimers Disease. Current Alzheimer Research, 2011, 8, 4-23.	0.7	42
81	Serotonin-containing projections to the thalamus in the rat revealed by a horseradish peroxidase and peroxidase antiperoxidase double-staining technique. Brain Research, 1984, 322, 233-243.	1.1	40
82	Early dysregulation of hippocampal proteins in transgenic rats with Alzheimer's disease-linked mutations in amyloid precursor protein and presenilin 1. Molecular Brain Research, 2004, 132, 241-259.	2.5	40
83	Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 69-84.	2.4	40
84	The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Molecular Psychiatry, 2021, 26, 6023-6037.	4.1	40
85	Glutamate-like immunoreactivity in medulla oblongata catecholamine/substance P neurons. NeuroReport, 1990, 1, 235-238.	0.6	39
86	Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease. Cerebral Cortex, 2016, 27, 1501-1511.	1.6	39
87	AF710B, an M1/sigmaâ€1 receptor agonist with longâ€lasting diseaseâ€modifying properties in a transgenic rat model of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 811-823.	0.4	39
88	Cognitive impairment and transmitterâ€specific pre―and postsynaptic changes in the rat cerebral cortex during ageing. European Journal of Neuroscience, 2007, 26, 3583-3596.	1.2	38
89	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. Trends in Neurosciences, 2014, 37, 629-641.	4.2	38
90	Imbalance towards inhibition as a substrate of aging-associated cognitive impairment. Neuroscience Letters, 2006, 397, 64-68.	1.0	35

#	Article	IF	CITATIONS
91	Perturbed mitochondria-ER contacts in live neurons modelling Alzheimer's disease amyloid pathology. Journal of Cell Science, 2019, 132, .	1.2	35
92	Derivatives of ganglioside GM1 as neuronotrophic agents: comparison of in vivo and in vitro effects. Brain Research, 1990, 513, 286-294.	1.1	34
93	BACE1 inhibition by microdose lithium formulation NPO3 rescues memory loss and early stage amyloid neuropathology. Translational Psychiatry, 2017, 7, e1190-e1190.	2.4	33
94	NPO3, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats. Journal of Alzheimer's Disease, 2020, 73, 723-739.	1.2	33
95	Chapter 32: Trophic responses of forebrain cholinergic neurons: a discussion. Progress in Brain Research, 1993, 98, 265-277.	0.9	32
96	Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-Aß agents. Acta Neuropathologica Communications, 2014, 2, 175.	2.4	32
97	Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis. Journal of Alzheimer's Disease, 2019, 67, 327-341.	1.2	32
98	Trigeminal antidromic vasodilation and plasma extravasation in the rat: Effects of sensory, autonomic and motor denervation. Brain Research, 1985, 346, 108-114.	1.1	31
99	Effects of nerve growth factor on cortical and striatal acetylcholine and dopamine release in rats with cortical devascularizing lesions. Brain Research, 1992, 577, 300-305.	1.1	31
100	Acidic FGF induces NGF and its mRNA in the injured neocortex of adult animals. Molecular Brain Research, 1995, 33, 1-6.	2.5	30
101	Worsening of memory deficit induced by energy-dense diet in a rat model of early-Alzheimer's disease is associated to neurotoxic Al² species and independent of neuroinflammation. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 731-743.	1.8	28
102	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5989-6001.	4.1	28
103	Hippocampal hyperactivity in a rat model of Alzheimer's disease. Journal of Neurochemistry, 2021, 157, 2128-2144.	2.1	28
104	Light and electron microscopic study of the distribution of substance P-immunoreactive fibers and neurokinin-1 receptors in the skin of the rat lower lip. Journal of Comparative Neurology, 2001, 432, 466-480.	0.9	27
105	Parasympathetic nerve fibers invade the upper dermis following sensory denervation of the rat lower lip skin. Journal of Comparative Neurology, 2004, 469, 83-95.	0.9	27
106	Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. Neurobiology of Aging, 2018, 67, 10-20.	1.5	27
107	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology, 2021, 185, 108081.	2.0	27
108	Targeting glutamatergic and cellular prion protein mechanisms of amyloid β-mediated persistent synaptic plasticity disruption: Longitudinal studies. Neuropharmacology, 2017, 121, 231-246.	2.0	26

#	Article	IF	CITATIONS
109	Uptake of [3H]dopamine in periglomerular cells of the rat olfactory bulb: an autoradiographic study. Brain Research, 1979, 165, 149-155.	1.1	24
110	Effects of coencapsulated NGF and GM1 in rats with cortical lesions. NeuroReport, 1993, 4, 971-974.	0.6	24
111	A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome. CNS and Neurological Disorders - Drug Targets, 2016, 15, 434-447.	0.8	24
112	Correlation of cognitive performance and morphological changes in neocortical pyramidal neurons in aging. Neurobiology of Aging, 2012, 33, 1466-1480.	1.5	23
113	Neocortical infarction in subhuman primates leads to restricted morphological damage of the cholinergic neurons in the nucleus basalis of Meynert. Brain Research, 1994, 648, 1-8.	1.1	22
114	Chapter 3 Organization of peptidergic neurons in the dorsal horn of the spinal cord: anatomical and functional correlates. Progress in Brain Research, 1995, 104, 41-59.	0.9	22
115	Ultrastructural and neurochemical analysis of synaptic input to trigemino-thalamic projection neurones in lamina I of the rat: A combined immunocytochemical and retrograde labelling study. Journal of Comparative Neurology, 1989, 285, 467-486.	0.9	21
116	MK-801 affects the potassium-induced increase of glial fibrillary acidic protein immunoreactivity in rat brain. Brain Research, 1992, 598, 286-293.	1.1	21
117	Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. Molecular Neurobiology, 2018, 55, 3451-3476.	1.9	21
118	IMMUNOCYTOCHEMISTRY AND NEUROBIOLOGY. Quarterly Journal of Experimental Physiology (Cambridge, England), 1983, 68, 545-578.	1.0	20
119	Immunoelectron microscopic evidence of nerve growth factor receptor metabolism and internalization in rat nucleus basalis neurons. Brain Research, 1990, 527, 109-115.	1.1	19
120	New Patterns of Intraneuronal Accumulation of the Microtubular Binding Domain of tau in Granulovacuolar Degeneration. Topics in Geriatrics, 1992, 5, 132-141.	0.9	19
121	Chapter 27 Trophic factor therapy in the adult CNS: remodelling of injured basalo-cortical neurons. Progress in Brain Research, 1994, 100, 213-221.	0.9	19
122	Changes with aging in the dopaminergic and noradrenergic innervation of rat neocortex. Neurobiology of Aging, 2011, 32, 2244-2253.	1.5	19
123	The Multi-Target Drug M30 Shows Pro-Cognitive and Anti-Inflammatory Effects in a Rat Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 373-383.	1.2	19
124	Effects of microencapsulated monosialoganglioside GM1 on cholinergic neurons. Brain Research, 1989, 496, 165-172.	1.1	18
125	Similarities in the ultrastructural distribution of nerve growth factor receptor-like immunoreactivity in cerebellar Purkinje cells of the neonatal and colchicine-treated adult rat. Journal of Comparative Neurology, 1991, 305, 189-200.	0.9	18
126	Microdose Lithium NPO3 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer's-like Amyloidosis. Current Alzheimer Research, 2018, 15, 1220-1230.	0.7	18

#	Article	IF	CITATIONS
127	Recovery of nucleus basalis cholinergic neurons by grafting NGF secretor fibroblasts. NeuroReport, 1992, 3, 353-356.	0.6	17
128	Intraventricular application of BDNF and NT-3 failed to protect nucleus basalis magnocellularis cholinergic neurones. NeuroReport, 1994, 5, 1105-1109.	0.6	17
129	Cortical peroxynitration of nerve growth factor in aged and cognitively impaired rats. Neurobiology of Aging, 2012, 33, 1927-1937.	1.5	17
130	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. Alzheimer's and Dementia, 2021, 17, 605-617.	0.4	17
131	Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease. Dialogues in Clinical Neuroscience, 2019, 21, 177-191.	1.8	17
132	The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy. Cells, 2022, 11, 16.	1.8	17
133	A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. Neurobiology of Disease, 2021, 148, 105150.	2.1	16
134	Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. European Journal of Pharmacology, 2017, 817, 7-19.	1.7	15
135	Storage and Release of Amines, Amino Acids and Peptides from Dendrites. Progress in Brain Research, 1982, 55, 205-224.	0.9	14
136	Preplaque (â€~Preclinical') Aβ-Induced Inflammation and Nerve Growth Factor Deregulation in Transgenic Models of Alzheimer's Disease-Like Amyloid Pathology. Neurodegenerative Diseases, 2012, 10, 104-107.	0.8	14
137	Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. Neurobiology of Disease, 2019, 127, 323-338.	2.1	14
138	Localization of Substance P in Neuronal Pathways. Novartis Foundation Symposium, 1982, , 55-83.	1.2	14
139	Hemicholinium mustard derivatives: Preliminary assesment of cholinergic neurotoxicity. Neurochemical Research, 1986, 11, 1091-1102.	1.6	13
140	Chapter 26 Cooperative effects of gangliosides on trophic factor-induced neuronal cell recovery and synaptogenesis: studies in rodents and subhuman primates. Progress in Brain Research, 1994, 101, 337-355.	0.9	13
141	Preparation and Characterization of New Anti-PSMA Monoclonal Antibodies with Potential Clinical Use. Hybridoma, 2007, 26, 363-372.	0.5	13
142	Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models. Life Sciences, 2012, 91, 1141-1147.	2.0	13
143	Inhibition of Endogenous NGF Degradation Induces Mechanical Allodynia and Thermal Hyperalgesia in Rats. Molecular Pain, 2013, 9, 1744-8069-9-37.	1.0	13
144	Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease. Frontiers in Pharmacology, 2019, 10, 189.	1.6	13

#	Article	IF	CITATIONS
145	Trigeminal antidromic vasodilatation and plasma extravasation in the rat: effects of acetylcholine antagonists and cholinesterase inhibitors. British Journal of Pharmacology, 1985, 84, 637-643.	2.7	12
146	TrkA antagonists decrease NGF-induced ChAT activity in vitro and modulate cholinergic synaptic number in vivo. Journal of Physiology (Paris), 1998, 92, 205-208.	2.1	12
147	Chronic Hippocampal Expression of Notch Intracellular Domain Induces Vascular Thickening, Reduces Glucose Availability, and Exacerbates Spatial Memory Deficits in a Rat Model of Early Alzheimer. Molecular Neurobiology, 2018, 55, 8637-8650.	1.9	12
148	Cognitive and brain cytokine profile of non-demented individuals with cerebral amyloid-beta deposition. Journal of Neuroinflammation, 2021, 18, 147.	3.1	11
149	Impact of Intracellular β-Amyloid in Transgenic Animals and Cell Models. Neurodegenerative Diseases, 2008, 5, 146-148.	0.8	10
150	Effect of antioxidant supplements on lipid peroxidation levels in primary cortical neuron cultures. Free Radical Biology and Medicine, 2019, 130, 471-477.	1.3	10
151	Gangliosides, NGF, Brain Aging and Disease: A Mini-Review with Personal Reflections. Neurochemical Research, 2012, 37, 1256-1260.	1.6	9
152	Early Long-Term Memory Impairment and Changes in the Expression of Synaptic Plasticity-Associated Genes, in the McGill-R-Thy1-APP Rat Model of Alzheimer's-Like Brain Amyloidosis. Frontiers in Aging Neuroscience, 2020, 12, 585873.	1.7	9
153	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 788-801.	2.4	8
154	Role of Immunology in Defining Transmitter-Specific Neurons. Immunological Reviews, 1987, 100, 279-306.	2.8	7
155	Two distinct monoclonal antibodies raised against mouse β nerve growth factor. Journal of Immunological Methods, 1991, 136, 247-257.	0.6	7
156	Microencapsulation and the Grafting of Genetically Transformed Cells as Therapeutic Strategies to Rescue Degenerating Neurons of the CNS. Reviews in the Neurosciences, 1995, 6, 15-33.	1.4	7
157	Responses of cortical noradrenergic and somatostinergic fibres and terminals to adjacent strokes and subsequent treatment with NGF and/or the ganglioside GM1. , 1997, 50, 627-642.		7
158	Platelets Bioenergetics Screening Reflects the Impact of Brain Aβ Plaque Accumulation in a Rat Model of Alzheimer. Neurochemical Research, 2019, 44, 1375-1386.	1.6	7
159	Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets. , 2007, , 1-27.		7
160	Choline Acetyltransferase Activity in the Rat Trigeminal System. Journal of Neurochemistry, 1985, 45, 1027-1029.	2.1	4
161	Nerve growth factor treatment restores [3H]QNB binding site density in adult rat subjected to cortical infarction. NeuroReport, 1995, 6, 419-420.	0.6	4
162	Editorial: The Involvement of NGF in the Alzheimer's Pathology. Frontiers in Neuroscience, 2019, 13, 872.	1.4	4

#	Article	IF	CITATIONS
163	Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	4
164	Synthesis and immunological evaluation of N-terminal, noncrossreactive tachykinin antigens. Journal of Medicinal Chemistry, 1988, 31, 1907-1910.	2.9	3
165	[No Title]. British Journal of Psychiatry, 1993, 163, 693-694.	1.7	3
166	P4â€013: Proâ€Cognitive and Antiâ€Inflammatory Effects of Af710B, a Mixed M1 Muscarinic/Sigmaâ€1 Receptor Agonist, in the Mcgillâ€Râ€Thy1â€App Rat Model of Human Adâ€Like Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P1019.	0.4	2
167	Editorial: Tau Pathology in Neurological Disorders. Frontiers in Neurology, 2021, 12, 754669.	1.1	2
168	Rita Levi-Montalcini, NGF Metabolism in Health and in the Alzheimer's Pathology. Advances in Experimental Medicine and Biology, 2021, 1331, 119-144.	0.8	2
169	Nerve Growth Factor. , 2013, , 1-9.		2
170	Theodore Lionel Sourkes obituary. Movement Disorders, 2015, 30, 446-447.	2.2	1
171	P3â€046: NP03 Inhibits Bace1 and GSKâ€3B for the Prevention of Early Alzheimer's‣ike Amyloid Neuropathology in Transgenic Rats. Alzheimer's and Dementia, 2016, 12, P834.	0.4	1
172	Leslie Iversen, a friend of friends and an inspiring light in neuropharmacology. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	1
173	Nerve Growth Factor Compromise in Down Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 719507.	1.7	1
174	Neurosciences: Spanish reflections and Cajal. Nature, 1984, 312, 499-499.	13.7	0
175	12 NGF and Alzheimer's disease. Neurobiology of Aging, 2012, 33, S6.	1.5	0
176	P4-222: NEW FORMULATION OF LITHIUM IMPROVES COGNITIVE PERFORMANCE IN EARLY STAGES OF ALZHEIMER-LIKE AMYLOID PATHOLOGY IN TRANSGENIC RATS. , 2014, 10, P869-P869.		0
177	Early and late inflammation in Alzheimer's pathology. Neurobiology of Aging, 2014, 35, S5.	1.5	0
178	IC-P-048: LONGITUDINAL FOLLOW-UP OF AMYLOIDOSIS AND GLUCOSE HYPOMETABOLISM IN A TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P28-P29.		0
179	IC-P-027: Dynamics of longitudinal biomarker changes in the Mcgill-R-Thy1-APP RAT. , 2015, 11, P27-P28.		0

#	Article	IF	CITATIONS
181	ICâ€Pâ€027: Amyloidâ€Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P28.	0.4	0
182	P1â€101: Amyloidâ€Beta 1â€42 (Aβ _{1â€42}) Levels in the Cerebrospinal Fluid Associate With Spatial Memory Performance in Aged But Not in Adult Mcgillâ€Râ€THY1â€APP Rats. Alzheimer's and Dementia, 2016, 12, P440.	0.4	0
183	ICâ€Pâ€099: Synergism Between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€6ubcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P75.	0.4	0
184	IC-P-101: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in AD Transgenic Rat Model. , 2016, 12, P77-P77.		0
185	P3â€⊋21: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in Alzheimer's Disease Transgenic Rat Model. Alzheimer's and Dementia, 2016, 12, P910.	0.4	0
186	O2â€02â€01: Dna Demethylation and Remethylation in Alzheimer's Pathology. Alzheimer's and Dementia, 2016, 12, P223.	0.4	0
187	The early and late inflammatory processes in the Alzheimer's pathology. Neurobiology of Aging, 2016, 39, S12.	1.5	0
188	[P4–035]: AMYLOID βâ€ÐRIVEN DNA DEMETHYLATION AS A TARGET FOR ALZHEIMER's DISEASE. Alzheimer's a Dementia, 2017, 13, P1269.	nd 0.4	0
189	[P3–159]: INTRANASAL INTERVENTION OF THE LXRSâ€APOEâ€MICROGLIA AXIS TO IMPROVE BRAIN BETAâ€AM CLEARANCE IN A TRANSGENIC MOUSE MODEL OF AD. Alzheimer's and Dementia, 2017, 13, P995.	YLQID	0
190	[P1–201]: REST HIPPOCAMPAL AND CORTICAL LEVELS CORRELATE WITH COGNITIVE PERFORMANCE IN A RAT MODEL OF EARLY ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P319.	0.4	0
191	[P1–209]: NGF AND BDNF DYSMETABOLISM IN A TRANSGENIC RAT MODEL OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P322.	0.4	0
192	[P1–001]: IDENTIFYING THE NEURONAL Aβâ€IMMUNOPOSITIVE POOL WITHIN THE HUMAN HIPPOCAMPUS. Alzheimer's and Dementia, 2017, 13, P231.	0.4	0
193	[P3–129]: EARLY AND LATE NEUROINFLAMMATORY EVENTS AS ALZHEIMER'S DISEASE PATHOLOGY EVOLVES IN DOWN SYNDROME INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P984.	0.4	0
194	[P1–111]: IMPAIRED REVERSAL OF HIPPOCAMPAL LONGâ€TERM POTENTIATION IN APPâ€OVEREXPRESSING RA <i>IN VIVO</i> . Alzheimer's and Dementia, 2017, 13, P283.	,TS 0.4	0
195	[ICâ€₽â€048]: ELEVATED CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH GRAY MATTER NEURODEGENERATION IN BOTH HUMANS AND TRANSGENIC RAT MODEL OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P41.	0.4	0
196	P3â€338: AMYLOID AND MICROGLIAL ACTIVATION SYNERGY LEADS TO HYPOMETABOLISM IN AD BRAIN: MICROPET LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P1211.	0.4	0
197	P2â€487: BUILDUP OF INTRACELLULAR Aβ ELICITS NEURONAL INFLAMMATION, INDEPENDENT OF PLAQUE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P740.	0.4	Ο
198	P2â€189: CHRONOLOGICAL CORRELATION BETWEEN LSD1, βâ€AMYLOID AND PROâ€INFLAMMATORY MARKERS COGNITIVE PERFORMANCE IN AN ADâ€LIKE TRANSGENIC RAT MODEL. Alzheimer's and Dementia, 2018, 14, P741	3 WITH 4	0

#	Article	IF	CITATIONS
199	P3â€153: VALIDATING LXRS/ABCA1/APOE AXIS INTERVENTION AS A POTENTIAL THERAPEUTIC TAGET TO PREVEN AMYLOID BETA CLEARANCE IMBALANCE. Alzheimer's and Dementia, 2018, 14, P1126.	0.4	0
200	P3â€093: VIRAL VECTORâ€MEDIATED OVEREXPRESSION OF HUMAN TAU IN THE RAT LOCUS COERULEUS: TAU LONGâ€TERM EXPRESSION AND PATHOLOGICAL CHANGES. Alzheimer's and Dementia, 2018, 14, P1101.	0.4	0
201	P3â€094: A NOVEL TRANSGENIC RAT MODEL OF TAUOPATHY WITH SEVERE BRAIN ATROPHY, GLIOSIS AND COGNITIVE DEFICITS. Alzheimer's and Dementia, 2018, 14, P1101.	0.4	0
202	Ted Sourkes, Moussa Youdim and I. Journal of Neural Transmission, 2020, 127, 119-123.	1.4	0
203	Evidence That Amyloid Pathology Progresses in a Neurotransmitter-Specific Manner. , 2008, , 393-401.		0